Details of the Drug Combination

General Information of Drug Combination (ID: DCAQ10R)

Drug Combination Name
Rufinamide Acetohydroxamic Acid
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Rufinamide   DMWE60C Acetohydroxamic Acid   DMYX7NI
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 1.88
Bliss Independence Score: 1.88
Loewe Additivity Score: 14.11
LHighest Single Agent (HSA) Score: 14.11

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rufinamide
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved (orphan drug) [2]
Pediatric lennox-gastaut syndrome 8A62.1 Approved [3]
Seizure disorder 8A6Z Approved [2]
Rufinamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [5]
------------------------------------------------------------------------------------
Rufinamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [6]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Acetohydroxamic Acid
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [4]
Acetohydroxamic Acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Urease (Bact ureC) TTAS2UO URE1_KLEAE Inhibitor [7]
------------------------------------------------------------------------------------
Acetohydroxamic Acid Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470).
3 Clinical pipeline report, company report or official report of Eisai.
4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018749.
5 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
6 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
7 Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.
8 New bispyridinium oximes: in vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning. Chem Biol Interact. 2008 Sep 25;175(1-3):413-6.